1 | 6/6, 6/9 | 6/5+3, 6/6+3 | | 0 1 | 1 2 | 40 mg/10 mg | | Treatment failure |
Initial control of inflammation followed by relapse on tapering treatment requiring higher doses of sirolimus with intolerable side effects |
| | | | | | | | Current medication: tacrolimus, prednisolone and sirolimus |
2 | 6/18, 6/12 | 6/9, 6/9 | | 3 3 | 0 0 | 40 mg/6 mg | | Symptom improvement: reduction of floaters |
3 | 6/36, 6/4 | 6/36, 6/4 | | 1 0 | 0 0 | Intermittent IV MP/0 mg | | Symptom improvement: reduction in pain and photophobia |
4 | 6/6+1, 6/12 | 6/5−1, 6/9 | | 1 1 | 0 0 | 30 mg/0 mg | | Reduction in vasculitis and regression of neovascularisation |
5 | 1/60, 6/18 | 1/60, 6/9 | | 1 2 | 0 0 | 40 mg/15 mg | | Treatment failure |
| | | | | | | | Despite reduction of inflammation mild CMO persists. Treatment withdrawn due to side effects |
| | | | | | | | Current medication: tacrolimus and oral corticosteroids |
6 | 6/5, 6/9 | 6/5, 6/5 | | 0 2 | 0 0 | 50 mg reducing to 20 mg/0 mg | | Symptom improvement: reduction in pain |
| | | | | | | | Regression of vasculitis with no further flare ups |
7 | 6/18, HM | 6/18, HM | | 0 0 | 0 0 | 15 mg/7.5 mg | | Marked improvement in systemic symptoms of Behçet’s syndrome |
| | | | | | | | Regression of vasculitis with no further flare ups |
8 | HM, 6/12 | HM, 6/12 | | 2 2 | 1 1 | Intermittent IV MP/6 mg and pulsed IV MP | | Treatment failure |
Continuing episodes of vasculitis leading to transient vision loss requiring repeated IV MP |
| | | | | | | | Currently on tacrolimus, prednisolone, and sirolimus |